Trastuzumab

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.

Trastuzumab
Trastuzumab Fab region (cyan) binding HER2/neu (gold)
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetHER2/neu
Clinical data
Trade namesHerceptin, Herceptin SC, others
Biosimilarstrastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, Herzuma, Herwenda, Kanjinti, Ogivri, Ontruzant, Trastucip, Trazimera, Tuzucip, Zercepac
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: D
Routes of
administration
Intravenous, subcutaneous
Drug classAntineoplastic agent
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismUnknown, possibly reticuloendothelial system
Elimination half-life2-12 days
Identifiers
CAS Number
PubChem SID
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard100.224.377
Chemical and physical data
FormulaC6470H10012N1726O2013S42
Molar mass145531.86 g·mol−1
 NY (what is this?)  (verify)

Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Other severe side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. Trastuzumab works by binding to the HER2 receptor and slowing down cell replication.

Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.